Supplementary Table 3. Association of clinicopathological features and magnitude of gene amplification of SOX2, FGFR1, and
PIK3CA
SOX2-amplified cases
FGFR1-amplified cases
PIK3CA-amplified cases
Low-Amp
High-Amp
Low-Amp
High-Amp
Low-Amp
High-Amp
(N = 17)
(N = 17)
(N = 9)
(N = 9)
(N = 26)
(N = 27)
N (%)
N (%)
P value
N (%)
N (%)
P value
N (%)
N (%)
P value
73 (39-84)
64 (58-81)
0.234
73 (43-84)
63 (57-76)
0.309
67 (39-84)
67 (47-84)
0.789
16 (94.1)
16 (94.1)
1.000
8 (88.9)
8 (88.9)
1.000
24 (92.3)
25 (92.6)
1.000
1 (5.9)
1 (5.9)
1 (11.1)
1 (11.1)
2 (7.7)
2 (7.4)
Never
1 (5.9)
0 (0)
1 (11.1)
0 ()
1 (3.8)
1 (3.7)
Ever
15 (88.2)
17 (100)
7 (77.8)
8 (88.9)
24 (92.4)
26 (96.3)
1 (5.9)
0 (0)
1 (11.1)
1 (11.1)
1 (3.8)
0 (0)
1 (5.9)
0 (0)
1 (11.1)
0 (0)
2 (7.7)
2 (7.4)
Squamous cell carcinoma
14 (82.3)
17 (100)
8 (88.9)
9 (100)
21 (80.8)
25 (92.6)
Others
2 (11.8)
0 (0)
0 (0)
0 (0)
3 (11.5)
0 (0)
Characteristic
Age, years
median (range)
Sex
Male
Female
Smoking status
Unknown
0.485
1.000
0.740
Histology
Adenocarcinoma
0.227
1.000
0.272
p-T
1/2/3/4
8/6/2/1
5/8/3/1
0.811
3/3/2/1
1/5/2/1
0.896
5/10/8/3
7/15/2/3
0.172
13/2/2/0
12/2/3/0
1.000
7/0/2/0
5/3/1/0
0.365
14/5/7/0
17/6/4/0
0.650
I
10 (58.8)
11 (64.7)
0.390
6 (66.7)
3 (33.3)
0.223
11 (42.3)
15 (55.6)
0.545
II
4 (23.5)
1 (5.9)
0 (0)
3 (33.3)
5 (19.2)
5 (18.5)
III
3 (17.7)
5 (29.4)
3 (33.3)
3 (33.3)
10 (38.5)
7 (25.9)
Yes
3 (17.7)
2 (11.8)
3 (33.3)
2 (22.2)
4 (15.4)
4 (14.8)
No
14 (82.3)
15 (88.2)
6 (66.7)
7 (77.8)
22 (84.6)
23 (85.2)
p-N
0/1/2/3
Pathological stage
Adjuvant
chemotherapy
1.000
1.000
Gene amplification levels were stratified into two groups (high amplification and low amplification) according to the cut-off median
values of the average target gene/CEP ratios for each gene probe set used for the FISH analyses.
1.000